NCT07472712 Integrating a Prescription Produce Program Within a Diabetes Prevention Program
| NCT ID | NCT07472712 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Virginia Commonwealth University |
| Condition | Type2diabetes |
| Study Type | INTERVENTIONAL |
| Enrollment | 100 participants |
| Start Date | 2026-05-26 |
| Primary Completion | 2028-05 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 100 participants in total. It began in 2026-05-26 with a primary completion date of 2028-05.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Type 2 Diabetes remains a major chronic disease among adults in the United States. A way to prevent Type 2 Diabetes is to engage in a diabetes prevention program. In the diabetes prevention program, individuals at risk of Type 2 Diabetes meet with a health coach to learn effective ways to build health behaviors around diet and physical activity. Individuals who participate in the diabetes prevention program are more likely to lose weight and eat a healthy diet.
Eligibility Criteria
Inclusion Criteria: * ≥age 18 * rationale: adolescents who are at-risk of T2DM may have unique needs that will not be addressed in this study * Most recent BMI ≥ 25kg/m 2 and not pregnant * rationale: elevated BMI is associated with higher risk of developing T2DM * Elevated glucose as evidenced by one of the following criteria: * Hemoglobin A1c 5.7-6.4% indicative of prediabetes within the last 36 months * Fasting blood glucose 100-125mg/dl or 2-hour glucose 140-199mg/dl within the last six months * Physician diagnosis of prediabetes (impaired fasting glucose, impaired glucose intolerance) * These criteria indicate the presence of prediabetes and places individuals are risk of T2DM * Speak, read, and understand English * rationale: current version of PPP intervention (cooking classes) is available in English * Have a working U.S.- based phone number * rationale: participants must have a working phone number because they will receive automated text messages as reminders to receive session reminders; participants must have a working phone number in case adverse event monitoring contacts are required * Able to attend study-related sessions at the Health Hub @ 25th over the year long study (i.e., weekly for 4 months, then monthly for 7 months) * rationale: participants must be able to attend study activities at the community site in order to engage in the intervention and study related sessions. Exclusion Criteria: * Individuals with HbA1c or glucose levels above the indicated glucose ranges will be advised to see their physician and excluded from participation unless they receive physician consent to participate. * Pregnant adults (\>18 years old) will not be included in this current study because prediabetes (HbA1c levels between 5.7% - 6.4% within the last 36 months) during pregnancy presents unique physiological challenges that the study intervention does not address. * Pregnancy status will be based on participants self-report. We will not provide any pregnancy tests prior to enrollment.
Contact & Investigator
Ana Diallo
PRINCIPAL INVESTIGATOR
Virginia Commonwealth University
Frequently Asked Questions
Who can join the NCT07472712 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Type2diabetes. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07472712 currently recruiting?
Yes, NCT07472712 is actively recruiting participants. Contact the research team at dialloa@vcu.edu for enrollment information.
Where is the NCT07472712 trial being conducted?
This trial is being conducted at Richmond, United States.
Who is sponsoring the NCT07472712 clinical trial?
NCT07472712 is sponsored by Virginia Commonwealth University. The principal investigator is Ana Diallo at Virginia Commonwealth University. The trial plans to enroll 100 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.